Evaluating an elevated screening PSA Test

JAMA - Journal of the American Medical Association

Volumn 314, Issue 19, 2015, Pages 2073-2074

  Barry, Michael J ^a   Hayes, Julia H ^b  

^a MASSACHUSETTS GENERAL HOSPITAL   (United States)

^b DANA FARBER CANCER INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

PROSTATE SPECIFIC ANTIGEN; TUMOR MARKER;

ADULT; CANCER PROGNOSIS; CANCER RISK; CANCER SCREENING; CASE REPORT; DIGITAL RECTAL EXAMINATION; GLEASON SCORE; HUMAN; MALE; MIDDLE AGED; PATIENT DECISION MAKING; PRIORITY JOURNAL; PROSTATE CANCER PROGNOSTIC TEST; PROSTATE HYPERTROPHY; PROTEIN BLOOD LEVEL; REVIEW; BLOOD; EVALUATION STUDY; PROBABILITY; PROSTATIC HYPERPLASIA; PROSTATIC NEOPLASMS; SENSITIVITY AND SPECIFICITY; WATCHFUL WAITING;

HUMANS; MALE; MIDDLE AGED; PROBABILITY; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC HYPERPLASIA; PROSTATIC NEOPLASMS; SENSITIVITY AND SPECIFICITY; WATCHFUL WAITING;

EID: 84947475439     PISSN: 00987484     EISSN: 15383598     Source Type: Journal    
DOI: 10.1001/jama.2015.12614     Document Type: Review

References (10)

1. Thompson IM, Ankerst DP, Chi C, et al. Operating characteristics of prostate-specific antigen in men with an initial PSA level of 3.0 ng/ml or lower. JAMA. 2005;294(1):66-70.
2. Hayes JH, Barry MJ. Screening for prostate cancer with the prostate-specific antigen test: A review of current evidence. JAMA. 2014;311(11): 1143-1149.
3. Ankerst DP, Hoefler J, Bock S, et al. Prostate Cancer Prevention Trial risk calculator 2.0 for the prediction of low-vs high-grade prostate cancer. Urology. 2014;83(6):1362-1367.
4. Schröder FH, Hugosson J, Roobol MJ, et al; ERSPC Investigators. Screening and prostate cancer mortality: results of the European Randomised Study of Screening for Prostate Cancer (ERSPC) at 13 years of follow-up. Lancet. 2014;384(9959): 2027-2035.
5. Gulati R, Gore JL, Etzioni R. Comparative effectiveness of alternative prostate-specific antigen-based prostate cancer screening strategies: model estimates of potential benefits and harms. Ann Intern Med. 2013;158(3):145-153.
6. Thompson IM Jr, Leach RJ, Ankerst DP. Focusing PSA testing on detection of high-risk prostate cancers by incorporating patient preferences into decision making. JAMA. 2014;312(10):995-996.
7. Wilt TJ, Brawer MK, Jones KM, et al; Prostate Cancer Intervention versus Observation Trial (PIVOT) Study Group. Radical prostatectomy versus observation for localized prostate cancer. N Engl J Med. 2012;367(3):203-213.
8. Vickers AJ, Till C, Tangen CM, Lilja H, Thompson IM. An empirical evaluation of guidelines on prostate-specific antigen velocity in prostate cancer detection. J Natl Cancer Inst. 2011;103(6):462-469.
9. ChoosingWisely. The PSA blood test for prostate cancer: when men need it-And when they don't. http://www.choosingwisely.org/patient-resources/psa-Test-for-prostate-cancer/. Accessed August 23, 2015.
10. CooperbergMR, Carroll PR. Trends in management for patients with localized prostate cancer, 1990-2013. JAMA. 2015;314(1):80-82.